Evotec has appointed Ingrid Müller as Chief Operating Officer (COO). She will be joining Evotec’s Management Board, effective 1 May 2026.
Müller brings more than 20 years of international leadership experience in the life sciences industry to the role, across operations, strategy, supply, procurement and R&D integration.
In her role as COO, Müller will oversee Evotec’s global operations and implementation of the Horizon initiative, with a focus on quality, productivity, scalability, delivery, cost and the continued advancement of technological improvements across the business.
Christian Wojczewski, CEO of Evotec, said: “Ingrid has built a broad international leadership profile defined by strategic perspective, operational discipline and the ability to lead cross-functional execution and transformation.
“She joins Evotec at a pivotal time, contributing a highly complementary combination of operational, strategic and scientific understanding, as we continue to advance our growth transformation.
“Her expertise in operational efficiency and delivery will play a key part in the execution of our strategy in coming years.”
Most recently, Müller served as Vice President Portfolio Strategy & Execution at CureVac. Prior to that, she held senior international leadership roles at Sanofi and Fresenius Kabi, where she was instrumental in strengthening supply resilience, implementing make-or-buy strategies, supporting growth and margin expansion, and delivering annual savings and cash-flow improvements.
Ingrid Müller, Evotec’s designated COO, added: “Evotec combines outstanding science, differentiated technology platforms and a clear commitment to making a meaningful difference. I look forward to working with colleagues across the global organisation to further strengthen operational excellence, quality and delivery for our partners, and to support Evotec’s next phase of focused and sustainable growth.”